Novartis Pharmaceuticals Corporation has received FDA approval for MEKIST (trametinib) dimethyl sulfoxide, marking an update to an existing product line. This approval retains the oral drug's status as a vital option for targeted cancer treatments, directly impacting the manufacturer's strategic positioning and therapeutic portfolio.